We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Occult cancer in patients with unprovoked venous thromboembolism: A nested case-control study.
- Authors
Sánchez-López, Verónica; Marín-Romero, Samira; Ferrer-Galván, Marta; Elías-Hernández, Teresa; Beristain, José Luis Lobo; Quincoces, Aitor Ballaz; Jara-Palomares, Luis; Martorell, Francisco Javier Rodríguez; Castro, María José; Hinojosa, Carmen Marín; López-Campos, José Luis; Otero-Candelera, Remedios
- Abstract
Objectives Detecting occult cancer in patients with unprovoked venous thromboembolism (VTE) remains a significant challenge. Our objective was to investigate the potential predictive role of coagulation-related biomarkers in the diagnosis of occult malignancies. Methods We conducted a nested case-control study with a 1-year prospective cohort of 214 patients with unprovoked VTE, with a focus on identifying occult cancer. At the time of VTE diagnosis, we measured various biomarkers, including soluble P-selectin (sP-selectin), dimerized plasmin fragment D (D-dimer), platelets, leukocytes, hemoglobin, total extracellular vesicles (EVs), EVs expressing tissue factor on their surface (TF+EVs), and EVs expressing P-selectin on their surface (Psel+EVs) in all participants. Results We observed statistically significant increased levels of sP-selectin (P =.015) in patients with occult cancer. Despite an increase in Psel+EVs, TF+EVs, D-dimer, and platelets within this group, however, no significant differences were found. When sP-selectin exceeded 62 ng/mL and D-dimer surpassed 10,000 µg/L, the diagnosis of occult cancer demonstrated a specificity of up to 91% (95% CI, 79.9%-96.7%). Conclusions The combination of sP-selectin and D-dimer can be a valuable biomarker in detecting occult cancer in patients with unprovoked VTE. Further research is necessary to ascertain whether easily measurable biomarkers such as sP-selectin and D-dimer can effectively distinguish between patients who have VTE with and without hidden malignancies.
- Subjects
THROMBOEMBOLISM; OCCULTISM; CANCER patients; CASE-control method; FIBRIN fragment D
- Publication
American Journal of Clinical Pathology, 2024, Vol 161, Issue 5, p501
- ISSN
0002-9173
- Publication type
Article
- DOI
10.1093/ajcp/aqad178